Introduction {#section5-1073274819846574}
============

Lung cancer (LC) and colorectal cancer (CRC) are 2 of the 5 most common types of cancer in the Netherlands,^[@bibr1-1073274819846574]^ with 12 600 and 15 000 new patients, respectively, diagnosed in 2015. With 5-year survival rates of 18% (LC) and 58% (CRC), survival is low.^[@bibr1-1073274819846574]^ Furthermore, patients with LC and CRC have the second and third highest hospital care costs of all patients with cancer.^[@bibr2-1073274819846574]^

Due to screening programs, more patients with cancer are identified at earlier disease stages. Cancer is increasingly becoming a chronic disease as a result of new chemotherapies and targeted therapies, meaning that the end-of-life (EoL) phase and the process of dying are longer and more gradual. The early detection of the palliative phase, advance care planning (ACP), and well-considered EoL care are therefore becoming increasingly important; however, we know that medical care can be both overused and underused.^[@bibr3-1073274819846574]^ It can be overused in patients with cancer who receive aggressive treatments during the EoL phase, which increases their burden while decreasing their quality of life.^[@bibr4-1073274819846574],[@bibr5-1073274819846574]^ The underuse of health care, for instance not having timely EoL discussions, is associated with higher costs and a lower quality of death and dying.^[@bibr6-1073274819846574]^

Key Points {#section1-1073274819846574}
----------

### Questions {#section2-1073274819846574}

What is the hospital health-care utilization of Dutch patients with lung cancer (LC) and colorectal cancer (CRC) in the end of life?

### Findings {#section3-1073274819846574}

We found that, for patients still receiving hospital care when death neared, the intensity of hospital care was high, yet palliative consultations were low. During the last month of life, chemotherapy and radiotherapy were significantly associated with more emergency department and intensive care unit visits in patients with LC.

### Conclusion {#section4-1073274819846574}

Palliative care is potentially underused in the end-of-life phase. Medical specialists should consider the intensity of treatments when discussing them with patients. Advance care planning can play a substantial role in this.

Analyzing the health-care utilization (HCU) of a patient group forms the first crucial step toward improving their health care and is a tool for the identification of the overuse and underuse of medical care. Here, we aim to present the HCU profiles (HCUP) of patients with LC and CRC using activity-based hospital data. This will provide complementary and contrasting information to the analysis of diagnosis-related group (DRG)--based hospital data, which was previously performed by Bekelman et al.^[@bibr7-1073274819846574]^

Materials and Methods {#section6-1073274819846574}
=====================

Study Population and Selection {#section7-1073274819846574}
------------------------------

This population-based cohort study includes insured Dutch persons (99% of the Dutch population)^[@bibr8-1073274819846574]^ who died in 2013, 2014, or 2015 with a diagnosis of LC and/or CRC for whom hospital medical care had been registered. The patients were included as patients with LC if they had been diagnosed with non-small-cell lung carcinoma or small-cell lung cancer, neoplasm bronchus lung, or small- and large-cell bronchus carcinoma. Patients with CRC were included if they had been diagnosed with colorectal malignancy or malignant neoplasm of the colon. Patients under 18 at the time of death or those who lacked a valid citizen service number and post code were excluded from the analysis.

Data {#section8-1073274819846574}
----

A national database of administrative hospital data at the health-care activity level was used in the analyses presented here. These activities are registered by all Dutch hospitals (8 academic and 92 general hospitals) and by more than 300 independent treatment centers. The data also contained information regarding the institution providing the care as well as the age and gender of the patients. For 2013 and 2014, the data covered 95% of the delivered and billable care. For 2015, this was approximately 70% due to the administrative delay in registries after care had been given.

Expert Panel {#section9-1073274819846574}
------------

Five medical experts were involved: 2 pulmonologists/oncologists and 3 experts specializing in internal medicine and oncology. All were specialized in palliative medicine. First, individual in-depth interviews were conducted with 4 experts using an interview guide to gain insights into their current practice and the background and reasons for the HCU patterns of Dutch patients with CRC or LC in the EoL phase. During the analysis phase, the experts classified each health-care activity into meaningful clusters ([Table 1](#table1-1073274819846574){ref-type="table"}) and compared the volume and intensity of EoL HCU to their experiences of daily practice. Also, the experts indicated which types of care had been registered too frequently in their opinion and what would be potential areas for improvement. Finally, the experts argued that unplanned and unwanted admissions such as ED contacts and days in ICU were important to investigate further. They formulated an additional question regarding the association between unwanted admissions and chemotherapy and radiotherapy. It was not possible to identify avoidable or unwanted hospital bed days from the available data; therefore, this study was focused on ICU days and ED contacts.

###### 

Clusters of Health-Care Activities and Descriptions.

![](10.1177_1073274819846574-table1)

  Category                                       Description
  ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inpatient days                                 
   Hospital bed wlays                            A first or subsequent clinical admission, classes A, B, and C
   ICU days                                      Low, medium, and high care in the ICU
  Outpatient days                                
   ED visit                                      Life support in the ED
   Ambulatory visit                              A first or return visit
  Specialty care consultations                   
   Palliative care consultation                  Specific health-care activity describing a palliative consultation
   Multidisciplinary consultation                Co-treatments with other specialists, (clinical) multidisciplinary consultation and activities
   Consultation                                  Consultations between patient and specialist, face-to-face or by telephone
   Allied and therapeutic care, per 15 minutes   All allied care and consultations, including physiotherapists, nutritionists, nurse practitioners, psychologists, social workers, optometrists, and geriatric rehabilitation
  Diagnostic tests                               
   Laboratory test                               All lab tests regarding hematology and small chemistry
   Noninvasive diagnostic test---pathological    Microbiological, histological and pathological (laboratory) tests
   Other noninvasive diagnostics                 CGA, spirograph tests, interpreting radiology results, preassessments, blood pressure measurement, audiometric tests, and so on
   Invasive diagnostics                          Includes colonoscopies and bronchoscopies, as well as biopsies and diagnostic punctures
  Imaging                                        
   Conventional radiology                        Ultrasounds and X-rays, Doppler, duplex, EEG
   CT scan                                       CT scans
   MRI scan                                      MRI scans
   PET scan                                      PET scans
   Nuclear scan other than PET                   SPECT and radioactive isotope tests
  Procedures and treatments                      
   Chemotherapy                                  Includes therapies as cisplatin, oxaliplatin, gemcitabin, docetaxel, and irinotecan
   CRC/LC surgery                                Surgeries registered under diagnosis codes specified in Table 1a and 1b, including tumor resection, tracheotomy, and therapeutic biopsies
   Non-CRC/LC surgery                            Surgeries other than the aforementioned, for instance, heart transplants; hip replacements, cataract, and hernia surgeries; and resections, reconstructions, and therapeutic biopsies
   Biologics                                     Includes therapies such as bevacizumab, rituximab, and gefitinib
   Radiotherapy                                  Radiation and radiotherapy fractions.
   Other (care and items)                        Pre- and post-surgery/chemotherapy/radiotherapy care, dental work, devices and implants (pacemaker, Steffeeplate, shunt), prosthetics, dialysis, injections, catheters, and so on

Abbreviations: CGA, comprehensive geriatric assessment; CRC, colorectal cancer; CT, computed tomography; ED, emergency department; EEG, electroencephalogram; ICU, intensive care unit; LC, lung cancer; MRI, magnetic resonance imaging; PET, positron emission tomography; SPECT, single photon computed tomography.

Clustering Health-Care Activities {#section10-1073274819846574}
---------------------------------

More than 13 000 different health-care activities were included in the database, many of which can be grouped together. The experts were therefore asked to define the important and relevant health-care clusters for the EoL phases of patients with CRC and LC separately; it was not necessary to identify the same categories for the 2 illnesses. Subsequently, 2 teams of experts appointed the 75% most frequently occurring health-care activities within each specialism to one of these categories. The process of defining the categories was iterative, meaning that within and between the 2 teams, the categories were adjusted and refined during the clustering process until a consensus was reached. One of the experts checked and finalized the clustering. The health-care activity codes for which no description was available (\<1%) and the additional costs for laboratory work, ICU admissions, house visits, or travel expenses were excluded because HCU, not health-care costs, were the focus of this investigation. Also, postmortem examinations were excluded from the clustering as these were not part of the EoL HCU.^[@bibr9-1073274819846574]^

Analyses {#section11-1073274819846574}
--------

The intensity of the HCU was examined by calculating the percentage of patients who received care described within the clusters and determining how often these care activities were performed on average per patient per month in the last 6, 3, and 1 month(s) before death. The associations between radiotherapy or chemotherapy and ICU days or ED contacts were also analyzed using a 2 × 2 frequency table, for which the corresponding odds ratios (OR) and 95% confidence intervals (CI) were calculated. The analyses were performed using SAS Enterprise Guide 9.2.

Results {#section12-1073274819846574}
=======

Patient Characteristics {#section13-1073274819846574}
-----------------------

The characteristics of the 25 533 patients with CRC and 14 911 patients with LC included in this study are presented in [Table 2](#table2-1073274819846574){ref-type="table"}. For both CRC and LC, more males than females passed away in the years 2013 to 2015.

###### 

Baseline Characteristics of All Patients with Lung or Colorectal Cancer who Died, 2013 to 2015.

![](10.1177_1073274819846574-table2)

                       Lung Cancer, N = 25 533   Colorectal Cancer, N = 14 911
  -------------------- ------------------------- -------------------------------
  Total                                          
   Gender, %                                     
    Male               15 324 (60.0%)            8494 (56.5%)
    Female             10 209 (40%)              6417 (43.5%)
   Mean age at death                             
    Male               70.6                      71.6
    Female             67.1                      72.1

Health-Care Utilization Profiles {#section14-1073274819846574}
--------------------------------

The main clusters of health-care activities for patients with CRC and LC are presented in [Table 1](#table1-1073274819846574){ref-type="table"}, while [Table 3](#table3-1073274819846574){ref-type="table"} shows the HCUP for these patients by cluster over 3 different time periods: 6 months, 3 months, and 1 month before death. It displays the proportion of patients who received a certain type of care and the average number of times they received it each month. In all 3 years, the 3 most frequently registered health-care activities for patients with both CRC and LC during the EoL phase were ambulatory visits, laboratory tests, and conventional radiology. Overall, the number of patients receiving hospital care decreased as their death neared, although the intensity of care per month increased for those still receiving it.

###### 

Hospital Care Utilization (HCU) Within the Last 6, 3, and 1 Month(s) of Life, the Number of Patients Receiving Certain Types of Care, and the Average Number of Times they Received it.

![](10.1177_1073274819846574-table3)

  --------------------------------------------- ----------------- ----------------- ----------------- ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------
  Colorectal cancer                             2013 (N = 5104)   2014 (N = 5683)   2015 (N = 4123)                                                                                                                                                    
  Months before death                           6                 3                 1                 6      3    1      6      3    1                                                                                                                 
                                                N                 \%                I^a^              N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I
  Inpatient days                                                                                                                                                                                                                                       
   Hospital bed days                            3235              63                1.8               2502   49   3.3    1364   27   8.8    3590   63   1.9    2742   48   3.4    1490   26   8.5    2275   55   1.8    1542   37   3.4    780    19   9.0
   ICU days                                     471               9                 1.0               379    7    2.0    287    6    5.2    490    9    1.0    374    7    1.9    264    5    5.3    249    6    1.0    175    4    2.0    122    3    5.5
  Outpatient days                                                                                                                                                                                                                                      
   ED visit                                     2613              51                0.2               1937   38   0.4    977    19   1.2    2924   52   0.2    2121   37   0.4    1097   19   1.2    1784   43   0.2    1121   27   0.4    539    13   1.2
   Ambulatory visit                             4788              94                0.5               4018   79   0.7    2039   40   1.5    5316   94   0.5    4290   76   0.7    2143   38   1.5    3755   91   0.5    2549   62   0.8    1078   26   1.6
  Specialty care consultations                                                                                                                                                                                                                         
   Palliative care consultation                 201               4                 0.3               162    3    0.5    100    2    1.4    266    5    0.3    226    4    0.5    147    3    1.6    128    3    0.3    104    3    0.6    56     1    1.6
   Multidisciplinary consultation               2198              43                0.5               1633   32   0.8    934    18   2.0    2579   45   0.4    1898   33   0.8    1068   19   1.9    1498   36   0.4    939    23   0.7    464    11   1.8
   Consultation                                 2924              57                0.4               2139   42   0.6    1026   20   1.7    3122   55   0.4    2149   38   0.7    940    17   1.8    2128   52   0.4    1304   32   0.7    493    12   1.8
   Paramedic and therapeutic care, per 15 min   2015              39                3.5               1487   29   6.4    776    15   17.8   2428   43   3.8    1838   32   7.0    931    16   18.9   1700   45   3.1    1097   29   5.8    523    14   16.8
  Diagnostic tests                                                                                                                                                                                                                                     
   Laboratory test                              4459              87                9.9               3673   72   18.0   2012   39   53.1   4984   88   10.2   3949   70   18.8   2093   37   51.7   3383   82   10.9   2315   56   21.0   1105   27   61.3
   Noninvasive diagnostic test---pathological   3823              75                1.1               2942   58   2.4    1485   29   7.1    4247   75   1.1    3148   55   2.1    1562   28   6.2    2652   64   1.2    1714   42   2.4    783    19   7.9
   Other noninvasive diagnostics                2651              52                0.3               1706   33   0.6    765    15   1.7    3058   54   0.3    1983   35   0.6    907    16   1.7    1954   47   0.3    1091   27   0.6    448    11   1.7
   Invasive diagnostics                         1907              37                0.3               1068   21   0.6    387    8    2.1    2000   35   0.3    1149   20   0.5    401    7    1.5    1260   31   0.3    628    15   0.5    192    5    1.6
  Imaging                                                                                                                                                                                                                                              
   Conventional radiology                       3388              66                0.4               2485   49   0.7    1287   25   1.9    3709   65   0.4    2618   46   0.8    1300   23   2.1    2342   57   0.4    1448   35   0.8    692    17   2.2
   CT scan                                      3248              64                0.3               2101   41   0.6    691    14   1.6    3578   63   0.3    2276   40   0.6    758    13   1.6    2307   56   0.3    1213   29   0.6    390    10   1.6
   MRI scan                                     686               13                0.2               390    8    0.5    97     2    1.5    794    14   0.2    409    7    0.5    102    2    1.4    457    11   0.2    191    5    0.5    35     1    1.3
   PET scan                                     275               5                 0.2               125    2    0.3    26     1    1.1    276    5    0.2    97     2    0.4    15     0    1.0    186    5    0.2    60     2    0.3    8      0    1.0
   Nuclear scan other than PET                  208               4                 0.2               103    2    0.4    21     0    1.4    237    4    0.2    115    2    0.5    29     1    1.4    116    3    0.2    47     1    0.4    11     0    1.0
  Procedures and treatments                                                                                                                                                                                                                            
   Chemotherapy                                 1333              26                0.7               792    16   1.0    236    5    2.2    1446   25   0.7    803    14   1.0    250    4    2.2    1127   27   0.8    548    13   1.2    136    3    2.8
   CRC surgery                                  440               9                 0.2               248    5    0.4    92     2    1.4    428    8    0.3    238    4    0.5    93     2    1.4    249    6    0.3    108    3    0.5    34     1    1.6
   Non-CRC surgery                              1097              22                0.3               584    11   0.5    175    3    1.3    1130   20   0.3    593    10   0.5    168    3    1.4    729    18   1.3    305    7    0.5    84     2    1.7
   Biologics                                    654               13                0.7               385    8    0.7    118    2    1.5    827    15   0.5    477    8    0.7    119    2    1.5    578    14   0.5    276    7    0.7    64     2    1.3
   Radiotherapy                                 667               13                1.5               424    8    2.5    142    3    6.4    728    13   1.4    464    8    2.3    140    3    5.7    396    10   1.3    207    5    2.0    50     1    5.2
   Other (care and items)                       3653              72                1.7               2830   55   4.3    1542   30   11.8   4022   71   2.3    3049   54   4.3    1511   27   10.4   2735   66   1.5    1799   44   3.0    806    20   9.5
  Lung cancer                                   2013 (N = 9124)   2014 (N = 9764)   2015 (N = 6643)                                                                                                                                                    
  Months before death                           6                 3                 1                 6      3    1      6      3    1                                                                                                                 
                                                N                 \%                I^a^              N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I      N      \%   I
  Inpatient days                                                                                                                                                                                                                                       
   Hospital bed days                            5978              66                1.7               4714   52   3.3    2712   30   9.0    6395   66   1.7    4936   51   3.3    2813   29   8.7    3799   57   1.7    2617   39   3.0    1421   21   8.9
   ICU days                                     435               5                 0.8               344    4    1.8    257    3    5.9    449    5    0.9    349    4    1.8    252    3    5.7    253    4    0.9    175    3    2.1    128    2    6.2
  Outpatient days                                                                                                                                                                                                                                      
   ED visit                                     5200              57                0.2               3998   44   0.4    2188   24   1.2    5534   57   0.2    4136   42   0.4    2186   22   1.2    3118   47   0.2    2093   32   0.4    1076   16   1.2
   Ambulatory visit                             8644              95                0.5               7467   82   0.7    4209   82   0.7    9164   94   0.5    7822   20   0.7    4264   44   1.6    6153   93   0.5    4560   16   0.4    2161   33   1.7
  Specialty care consultations                                                                                                                                                                                                                         
   Palliative care consultation                 264               3                 0.3               229    3    0.5    167    2    1.5    338    4    0.2    279    3    0.5    195    2    1.5    135    2    0.3    110    2    0.6    69     1    1.7
   Multidisciplinary consultation               4754              52                0.4               3616   40   0.7    2036   22   2.0    5327   55   0.4    4030   41   0.7    2283   23   1.9    3028   46   0.3    2047   31   0.6    1062   16   1.8
   Consultation                                 551               60                0.3               4196   47   0.6    2041   22   1.4    5940   61   0.4    4436   45   0.6    2076   21   1.6    3683   55   0.4    2331   35   0.6    1014   15   1.7
   Paramedic and therapeutic care, per 15 min   4043              44                2.8               3023   33   5.1    1604   18   12.7   4639   48   2.7    3502   36   4.8    1886   19   12.3   3012   45   2.5    2078   31   3.9    1073   16   11.8
  Diagnostic tests                                                                                                                                                                                                                                     
   Laboratory test                              7755              85                8.1               6317   69   15.1   3515   39   46.6   8237   84   8.7    6549   67   16.2   3559   37   48.2   5361   81   8.7    3740   56   16.3   1883   28   50.3
   Noninvasive diagnostic test---pathological   7016              77                0.9               5386   59   1.7    2830   31   5.6    7492   77   1.0    5673   58   2.0    2936   30   6.1    4581   69   1.0    3045   46   2.2    1486   22   6.5
   Other noninvasive diagnostics                5577              62                0.4               3775   41   0.6    1764   19   1.7    6048   62   0.4    4135   42   0.7    1875   19   1.8    3705   56   0.4    2248   34   0.6    958    14   1.8
   Invasive diagnostics                         4081              45                0.3               2353   26   0.6    868    10   1.6    4247   44   0.3    2408   25   0.5    887    9    1.5    2520   38   0.3    1296   20   0.5    439    7    1.5
  Imaging                                                                                                                                                                                                                                              
   Conventional radiology                       7218              79                0.4               5664   62   0.7    2906   32   2.0    7658   78   0.4    5826   60   0.8    2980   31   2.2    4779   72   0.4    3226   49   0.8    1553   23   2.3
   CT scan                                      5920              65                0.3               3993   44   0.6    1485   16   1.6    6409   66   0.3    4280   44   0.6    1555   16   1.6    4050   61   0.3    2350   35   0.5    789    12   1.6
   MRI scan                                     2423              27                0.2               1396   15   0.5    406    4    1.4    2600   27   0.2    1517   16   0.5    446    5    1.3    1545   23   0.2    831    13   0.5    210    3    1.4
   PET scan                                     1795              20                0.2               808    9    0.3    170    2    1.0    2083   21   0.2    936    10   0.3    206    2    1.0    1147   21   0.2    468    10   0.3    110    2    1.0
   Nuclear scan other than PET                  1295              14                0.2               634    7    0.4    157    2    1.3    1422   15   0.2    658    7    0.4    157    2    1.3    832    15   0.2    364    7    0.4    90     2    1.3
  Procedures and treatments                                                                                                                                                                                                                            
   Chemotherapy                                 2724              30                0.8               1667   18   1.2    549    6    2.7    3054   31   0.7    1821   19   1.0    582    6    2.3    1969   40   0.7    983    15   0.8    260    4    2.4
   LC surgery                                   87                1                 0.2               47     1    0.4    19     0    1.4    79     1    0.2    47     1    0.4    11     0    1.1    55     1    0.2    34     0    0.3    14     0    1.0
   Non-LC surgery                               1355              15                0.2               689    8    0.4    199    2    1.3    1403   14   0.2    725    7    0.5    211    2    1.2    821    12   1.5    365    6    0.5    101    2    1.5
   Biologics                                    128               1                 0.4               75     1    0.7    20     0    1.2    132    1    0.4    72     1    0.6    18     0    1.5    73     1    0.4    31     1    0.5    9      0    1.5
   Radiotherapy                                 2797              31                1.6               1898   21   2.4    707    8    5.1    2998   31   1.5    2020   21   2.5    714    7    5.7    1420   21   1.5    821    12   1.7    263    4    5.2
   Other (care and items)                       6181              68                1.4               4732   52   2.6    2452   27   8.5    6647   68   1.6    5050   52   2.8    2521   26   9.7    4112   62   1.1    2757   42   2.3    1292   19   7.0
  --------------------------------------------- ----------------- ----------------- ----------------- ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------ ------ ---- ------

Abbreviations: CRC, colorectal cancer; CT, computed tomography; ED, emergency department; I, Intensity; ICU, intensive care unit; LC, lung cancer; MRI, magnetic resonance imaging; PET, positron emission tomography.

^a^Intensity is the average number of treatments per patient per month for the patients who received a particular treatment.

In 2015, during their last 6 months of life, 55.2% of patients with CRC and 57.2% of patients with LC were admitted to hospital (not including ICU and ER admissions). In the last month of life, these proportions decreased to 18.9% and 21.4%, respectively, with an average stay of 9 hospital bed days. For patients who visited the ICU (2%-3%) and the ED (13%-16%) during their last month of life, the numbers of ICU days and ED contacts during this period were 5.5 days and 1.2 times, respectively, for patients with CRC and 6.2 days and 1.2 times for patients with LC.

Less than 2% of all patients had a palliative care team consultation in their last month of life ([Table 3](#table3-1073274819846574){ref-type="table"}), while up to 20% of the patients with CRC and 23% of the patients with LC had a (multidisciplinary) consultation with their health-care specialist in this timeframe.

During the last 6 months of life, up to 66% of the patients with CRC and 79% of the patients with LC underwent conventional radiology. A total of 56% to 64% of patients with CRC and 61% to 66% for patients with LC received a computed tomography (CT) scan during this period, which dropped to 10% to 14% for CRC and 12% to 16% for LC during the last month of the patient's life.

During their last 6 months of life, a small number of patients received cancer-related surgery, representing 9% of the patients with CRC and 1% of the patients with LC. No more than 1% of patients with LC received biologics, although 13% to 15% of patients with CRC received these treatments throughout the whole EoL phase. The opposite was true for radiotherapy, as up to 31% of the patients with LC received this treatment compared to just 13% of patients with CRC in the last 6 months of life. Overall, in the last month of life, we found that a very low percentage of patients underwent cancer-specific treatments and procedures.

Association Between Chemotherapy/Radiotherapy and ED Contacts {#section15-1073274819846574}
-------------------------------------------------------------

Patients with CRC receiving chemotherapy had more ED contacts during their last 6 months before death than patients who did not undergo chemotherapy during this period (unadjusted odds ratio \[OR\] = 1.8, 95% confidence interval \[CI\] = 1.6-2.1; [Table 4](#table4-1073274819846574){ref-type="table"}). During the last month of life, the OR increased to 17.2 (95% CI = 11.8-25.0). We observed a similar increase in patients with LC (OR = 2.0 six months before death, 95% CI = 1.8-2.2; OR = 15.8 one month before death, 95% CI = 12.0-20.9). Patients with both CRC and LC receiving radiotherapy in their last month of life were significantly more frequently admitted to the ED than patients who did not undergo radiotherapy (OR for patients with CRC = 4.6, 95% CI = 2.6-8.1; OR for patients with LC = 4.2, 95% CI = 3.2-5.4).

###### 

Number of Patients With ED Contacts or ICU Days and the Number of Patients who Underwent Radiotherapy or Chemotherapy in 2015.

![](10.1177_1073274819846574-table4)

                                 Chemotherapy, N (%)   No chemotherapy, %   Crude OR \[95%CI\]       Radiotherapy, %   No radiotherapy, %   Crude OR \[95%CI\]
  ------------------------------ --------------------- -------------------- ------------------------ ----------------- -------------------- ---------------------
  Colorectal cancer (N = 4123)   N = 1127              N = 2996                                      N = 396           N = 3727             
  Last 6 months of life                                                                                                                     
   ≥1 ED-contact                 610 (54.1)            1174 (39.2)          1                        183 (46.2)        1603 (43.0)          1
   No ED-contact                 517 (45.9)            1822 (60.8)          **1.8 \[1.6-2.1\]**      213 (53.8)        2124 (57.0)          1.1 \[0.9-1.4\]
   ≥1 ICU-day(s)                 44 (3.9)              204 (6.8)            1                        23 (5.8)          227 (6.1)            1
   No ICU-day                    1083 (96.1)           2792 (93.2)          **0.6 \[0.4-0.8\]**      373 (94.2)        3500 (93.9)          1.0 \[0.6-1.5\]
                                 N = 136               N = 3987                                      N = 50            N = 4073             
  Last month of life                                                                                                                        
   ≥1 ED-contact                 93 (68.4)             447 (11.2)           1                        20 (40.0)         517 (12.7)           1
   No ED-contact                 43 (31.6)             3540 (88.8)          **17.2 \[11.8-25.0\]**   30 (60.0)         3556 (87.3)          **4.6 \[2.6-8.1\]**
   ≥1 ICU-day(s)                 6 (4.4)               116 (2.9)            1                        3 (6.0)           118 (2.9)            1
   No ICU-day                    130 (95.6)            3871 (97.1)          1.5 \[0.7-5.6\]          47 (94.0)         3955 (97.1)          2.1 \[0.7-6.9\]
  Lung cancer (N = 6643)         N = 1969              N = 4674                                      N = 1420          N = 5223             
  Last 6 months of life                                                                                                                     
   ≥1 ED-contact                 1158 (58.8)           1963 (42.0)          1                        728 (51.3)        2397 (45.8)          1
   No ED-contact                 811 (41.2)            2711 (58.0)          **2.0 \[1.8-2.2\]**      692 (48.7)        2836 (54.2)          **1.3 \[1.1-1.4\]**
   ≥ 1 ICU-day(s)                57 (2.9)              196 (4.2)            1                        43 (3.0)          209 (4.0)            1
   No ICU-day                    1912 (97.1)           4478 (95.8)          **0.7 \[0.5-0.9\]**      1377 (97.0)       5024 (96.0)          0.7 \[0.5-1.0\]
                                 N = 260               N = 6383                                      N = 263           N = 6380             
  Last month of life                                                                                                                        
   ≥ 1 ED-contact                187 (71.9)            887 (13.9)           1                        112 (42.6)        963 (15.1)           1
   No ED-contact                 73 (28.1)             5496 (86.1)          **15.8 \[12.0-20.9\]**   151 (57.4)        5417 (84.9)          **4.2 \[3.2-5.4\]**
   ≥ 1 ICU-day(s)                13 (5.0)              115 (1.8)            1                        8 (3.0)           121 (1.9)            1S
   No ICU-day                    247 (95.0)            6281 (98.4)          **2.9 \[1.6-5.2\]**      255 (97.0)        6259 (98.1)          **2.7 \[1.3-5.6\]**

Abbreviations: CI, confidence interval; ED, emergency department; ICU, intensive care unit; OR, odds ratio.

Bold face values -- Level of significance *p* \< 0.05.

Association Between Chemotherapy/Radiotherapy and ICU Contacts {#section16-1073274819846574}
--------------------------------------------------------------

Patients receiving chemotherapy 6 months before their death spent fewer days in the ICU than patients who did not undergo this treatment. We observed that, in the last month of life, patients with LC undergoing chemotherapy were admitted to the ICU (OR = 2.9, 95% CI = 1.6-5.2) more often than those who did not receive chemotherapy during this period. Patients with LC receiving radiotherapy in their last month of life were significantly more frequently admitted to the ICU than patients who did not undergo this treatment (OR = 2.7, 95% CI: = 1.3-5.6).

Discussion {#section17-1073274819846574}
==========

We revealed that a substantial number of patients with LC and CRC received highly intensive treatments during their EoL phase. Receiving chemotherapy or radiotherapy in the last month of life was found to be strongly associated with increased ER and ICU contacts in patients with LC.

Our results regarding hospital admissions are comparable to those of Bekelman et al who reported that 7% of elderly Dutch patients who died of cancer in 2010 spent 1 or more day(s) in ICU during their last 30 days of life, while 42% were hospitalized in an acute-care hospital.^[@bibr7-1073274819846574]^ They also found that ICU admissions were more than twice as common in the United States than in the other 6 reporting countries for patients with cancer, including the Netherlands. Teno et al reported that 29.2% of all (Medicare-supported) patients with cancer in the United States were admitted to the ICU during their last 30 days of life (data from 2009).^[@bibr10-1073274819846574]^ These findings were substantially higher than those of the present study (3% to 5%); however, the Netherlands has one of the lowest rates of ICU admissions among the 8 countries investigated by Teno et al.^[@bibr10-1073274819846574]^ Although these findings show that HCU during the EoL phase is lower in the Netherlands than in other countries, overuse (or underuse) could still be present.

The medical experts included in this study indicated that the HCUPs we identified corresponded with their experience of daily oncological practice, describing them as "shockingly intense." According to them, the potential areas for improvement in EoL care are to reduce the high number of admissions to the ICU and ER, to reduce the number of patients receiving a CT scan and the overall number of scans each patient receives, and to increase the number of palliative care consultations held with patients. We will discuss each of these themes and their level of appropriateness below.

Unwanted hospital admissions may be necessitated by a prolonged treatment during the EoL phase, as doctors may find it difficult to cease high-impact treatments such as chemotherapy and biological treatment in a timely manner^[@bibr11-1073274819846574]^ and might not always discuss preferences and treatment aims with the patient.^[@bibr12-1073274819846574]^ We argue that unplanned and even unwanted admissions could be prevented by timely discussions regarding EoL care or ACP. Palliative care consultations are a means of giving patients a more central role in their health care and the medical decisions surrounding their EoL.^[@bibr13-1073274819846574]^ Although ACP has its pros and cons, recent studies have shown that ACP is able to improve the overall compliance with patient EoL wishes and improve the satisfaction of the patients and their families. It also reduces family stress, anxiety, and depression,^[@bibr14-1073274819846574][@bibr15-1073274819846574]-[@bibr16-1073274819846574]^ while increasing the quality of life and survival rates in comparison to standard care^[@bibr16-1073274819846574]^ and significantly lowering health-care costs.^[@bibr6-1073274819846574],[@bibr17-1073274819846574]^ Despite these benefits, there is currently little evidence to indicate whether palliative care interventions implemented in the hospital, home, or outpatient clinic are more effective than standard care practices at reducing ED visits among patients with cancer during their EoL phase.^[@bibr18-1073274819846574]^

Unfortunately, the number of patients receiving palliative care consultations in our study was exceptionally low. One explanation for this might be that, in the Dutch health-care system, the DRG data on palliative consultations are only registered as palliative care when a multidisciplinary team is actively providing palliative care, there has been at least 1 clinical or ambulant consultation, and the patient is solely receiving palliative care with no other curative treatments. A palliative consultation can be registered as a health-care activity; however, when the activity is not registered as palliative care, it is not sent to the database we used for our analyses. Although the number of palliative teams in Dutch hospitals is increasing,^[@bibr19-1073274819846574]^ supportive care specialists are only involved in the care of 12% of non-sudden-death patients during their last month of life.^[@bibr20-1073274819846574]^ Also, other reported data suggest that 20% to 25% of a representative sample of Dutch patients with CRC and LC had a palliative treatment aim in the 3 months before their deaths as recorded by their general practitioners (GPs).^[@bibr21-1073274819846574]^ The percentage of patients who receive palliative consultations and the total number of these consultations might therefore be higher than our results suggest, although they are still likely to be relatively uncommon.

Our results suggest that high-impact treatments are associated with an increase in both days spent in the ICU in the last month of life for patients with LC and the number of ED contacts made throughout the entire EoL phase for both patients with LC and CRC. We cannot conclude that these treatments are inappropriate in the EoL phase on the basis of this study, however, as more information regarding the treatment aims and patient preferences would be required to make this determination. The association we found could reflect 2 nonexclusive contrasting possibilities: Patients receiving chemotherapy may end up in the ED/ICU more often than those who do not receive chemotherapy/radiotherapy due to an increase in complications, or their ED/ICU admission may lead to chemotherapy treatments; for instance, if a palliative treatment aim is determined after their admission. Studies have shown conflicting and inconclusive results regarding (palliative) chemotherapy^[@bibr22-1073274819846574][@bibr23-1073274819846574]-[@bibr24-1073274819846574]^; however, regardless of the direction of this association, our data suggest that high-intensity care (whether chemotherapy or an ICU admission) is associated with the patient receiving other highly intensive care. Medical specialists should consider the intensity of these treatments when discussing them with their patients. Bearing in mind that 80% of patients would prefer to die at home^[@bibr25-1073274819846574],[@bibr26-1073274819846574]^ but only 61% actually do,^[@bibr26-1073274819846574]^ we must ask whether this trend is acceptable.

Although they are important for the initial staging process of the cancer with acceptable cost-effectiveness parameters and even cost savings,^[@bibr27-1073274819846574]^ a CT scan might be unnecessary if it will not make a difference to the subsequent treatment. Schnipper et al even stated that "until high-level evidence demonstrates that routine surveillance with PET or PET/CT scans helps prolong life or promote wellbeing after treatment for a specific type of cancer, this practice should not be performed."^[@bibr28-1073274819846574](p4365)^ Given this recommendation, it is remarkable that an average of 1.6 CT scans were still performed on almost 10% of patients in their final month of life or an average of 0.6 times for almost 30% of patients during their final 3 months.

Strengths and Limitations {#section18-1073274819846574}
-------------------------

A major strength of our study was the analysis of the data at the level of health-care activities. Although our database only included hospital data, the use of these data enabled us to analyze HCU in detail. Furthermore, the involvement of a panel of medical experts enabled us to gather specialized input and opinions and subsequently understand and interpret the results. Our data were shown to be representative, as the mean age at death and the male--female ratio for both cancer types were comparable to the national mortality data.^[@bibr1-1073274819846574]^

Our study also had some limitations, such as the fact that we were not able to distinguish between curative and palliative treatments in these data. This is important, as it would give more insight into possible explanations for the HCU we have found in our study. Also, registered health care does not always necessarily reflect the actual health care supplied; faulty registrations or nonregistrations do occur. Furthermore, the 2015 database was not complete at the time of this study due to the time-consuming process of collecting data from Dutch hospitals. When comparing the data from each year, however, we found that our results were robust. We therefore argue that the incompleteness of the data did not substantially alter the image of the HCUP.

Although high-intensity hospital care is given to patients in the EoL phase, some patients received no hospital-based care. We were unable to investigate the differences in characteristics and HCU between these 2 groups, but we believe that the hospital-based patients are most likely to receive high-intensity and high-cost, maybe even inappropriate, care during the EoL phase in comparison to the nonhospital-based patients. We do not know whether the care for nonhospital-based patients was more appropriate than the hospital care provided to other patients. In order to further investigate this, any geographical or institutional variations in HCU within the Netherlands need to be identified, as these are even stronger indications of potential overuse and underuse. We also need to broaden the scope of future studies by analyzing the full health-care chain to determine which types of primary care were provided for patients with high levels of secondary care utilization and to identify the underlying reasons for differences in HCU. The ultimate aim would be to signal the overuse and underuse of health care while also understanding it, leading to better conversations between physicians/institutions and patients to improve quality of care.

In conclusion, we observed a high usage of intense care in the EoL phase of patients with CRC and LC in the Netherlands, which may represent the overuse of health care, especially regarding hospital admissions and CT scans. Palliative care needs to be further improved and developed in the EoL phase and may currently be underused. Advanced care planning can play a substantial role in ensuring the appropriate use of palliative care. More research is necessary to identify the true overuse and underuse of hospital medical services.
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